SGLT2i vs placebo
Heart failure hospitalisation (RR) · CVD (ASCVD, HF, or both)
SGLT2i leads to lower hospitalisation for HF compared with placebo (high certainty).
1 finding from 1 review
- Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2… 2021 · Cochrane Headline outcomes onlyOR 0.65 [0.59, 0.71]5 studies · 24962 participantsHigh